KML29 is primarily researched for its potential therapeutic applications, particularly in the field of neuroscience and pain management. It functions as a selective inhibitor of the enzyme diacylglycerol lipase-alpha (DAGL-α), which plays a crucial role in the biosynthesis of endocannabinoids. By inhibiting DAGL-α, KML29 reduces the production of 2-arachidonoylglycerol (2-AG), a key endocannabinoid involved in regulating synaptic plasticity, inflammation, and pain signaling.

In preclinical studies, KML29 has shown promise in alleviating chronic pain conditions, such as neuropathic pain, without the side effects commonly associated with traditional cannabinoid-based therapies. Its ability to modulate the endocannabinoid system selectively makes it a potential candidate for treating conditions like multiple sclerosis, epilepsy, and inflammatory disorders. Additionally, KML29 is being explored for its neuroprotective properties, which could be beneficial in neurodegenerative diseases like Alzheimer’s and Parkinson’s. Further research is ongoing to fully understand its efficacy and safety profile in clinical settings.